thalidomide has been researched along with piroxicam in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barbanera, A; Finotello, R; Laganga, P; Marconato, L; Polton, G; Rohrer Bley, C; Rossi, F; Sabattini, S; Stiborova, K; Vasconi, ME | 1 |
| Marconato, L; Rossi, F; Sabattini, S; Vascellari, M | 1 |
1 review(s) available for thalidomide and piroxicam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for thalidomide and piroxicam
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Dog Diseases; Dogs; Female; Lung Neoplasms; Male; Piroxicam; Survival Analysis; Thalidomide | 2018 |
The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Indoles; Mammary Neoplasms, Animal; Neoplasm Staging; Piroxicam; Pyrroles; Radiation Dose Hypofractionation; Thalidomide; Treatment Outcome | 2018 |